Clinical trial
Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced…
NCT00474786 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00474786 |
|---|---|
| Title | Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib |
| Official title | A Randomized Trial Of Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced Renal Cell Carcinoma Who Have Failed First-Line Sunitinib Therapy |
| Acronym | INTORSECT |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Renal Cell Carcinoma |
| Intervention type | Drug |
| Interventions | Sorafenib, temsirolimus (Torisel) |
| Enrollment | 512 |
| Start date | Sep 1, 2007 |
| Primary completion | Jan 1, 2012 |
| Completion | Jan 1, 2013 |
| First posted | May 17, 2007 |
| Last update posted | Nov 21, 2013 |
| Countries | Argentina, Australia, Austria, Canada, Chile, China, Denmark, Finland, France, Germany, Hungary, Italy and 8 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: